.png){kind=icon}
.png){kind=icon}
Return
Breaking barriers: Enhancing access to dementia clinical trials in the United Kingdom—Insights from the Scientific Advisory Board of the Dame Barbara Windsor Dementia Goals Programme
.png){kind=icon}
OA
AI
R
J
S
E
H
S
R
C
S
C
J
DOI：10.1002/alz.71621.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
The Dame Barbara Windsor Dementia Goals Programme was launched by the UK Government to accelerate the development and delivery of new treatments for dementia. We present the recommendations from the Scientific Advisory Board, to enable timely access to therapies for the wider population, reducing health system burden while improving patient outcomes. The recommendations focus on three areas: (i) establishing a new dynamic national patient registry for clinical trial recruitment; (ii) the use of biomarkers to improve early and accurate diagnosis; and (iii) a framework for end-to-end implementation across the landscape of healthcare, research and regulators. A Brain Aging Registry for Biomarkers, Access to trials, Research and Adoption would support recruitment, monitoring, and personalized care. Embedding digital and biomarker innovations into routine care would improve personalized and equitable dementia services, with earlier diagnosis and more effective prevention. Robust patient and public involvement is required, to ensure transparency, trustworthiness, and meaningful participation.
Keywords:
clinical trials
cohorts
pharma
registry
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
A
IF:
0
Papers:
511
Citations:
0
View more organizations